A dual kinase inhibitor* is entering a clinical trial for advanced pancreatic cancer in combination with gemcitabine as part of Cancer Research UK’s Combinations Alliance. The novel combination of drugs targets the process of nerve invasion, observed in over 80% of pancreatic ductal adenocarcinoma (PDAC) and is associated with tumour spread and severe pain.
Read more at: https://www.cancerresearchuk.org/about-us/cancer-news/press-release/2019-05-17-cancer-research-uk-to-test-targeted-drug-in-pancreatic-cancer